International Journal Of Bilogical Sciences
.: Home > International Journal Of Bilogical Sciences > 2014 > Volume 10 Number 2 > Weiyan Xie, Hongyun Wang, Yue He, Dan Li, Lei Gong, Yazhuo Zhang
CDK5 and Its Activator P35 in Normal Pituitary and in Pituitary Adenomas: Relationship to VEGF Expression
Weiyan Xie, Hongyun Wang, Yue He, Dan Li, Lei Gong, Yazhuo Zhang
Beijing Neurosurgical Institute, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing 100050, China. Corresponding author: Ya-Zhuo Zhang, Beijing Neurosurgical Institute, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing 100050, China (Tel: +86-10-67022886 Fax: +86-10-67057391, Email:email@example.com).
Pituitary tumors are monoclonal adenomas that account for about 10–15% of intracranial tumors. Cyclin-dependent kinase 5 (CDK5) regulates the activities of various proteins and cellular processes in the nervous system, but its potential roles in pituitary adenomas are poorly understood. The kinase activity of CDK5 requires association with an activating protein, p35 (also known as CDK5 activator 1, p35). Here, we show that functional CDK5, associated with p35, is present in normal human pituitary and in pituitary tumors. Furthermore, p35 mRNA and protein levels were higher in pituitary adenomas than in the normal glands, suggesting that CDK5 activity might be upregulated in pituitary tumors. Inhibition of CDK5 activity in rat pituitary cells, reduced the expression of vascular endothelial growth factor (VEGF), a protein that regulates vasculogenesis and angiogenesis. Our results suggest that increased CDK5-mediated VEGF expression might play a crucial role in the development of pituitary adenomas, and that roscovitine and other CDK5 inhibitors could be useful as anticancer agents.
Cdk5; p35; VEGF; pituitary adenomas; expression.
Date Deposited : 03 Feb 2016 11:18
Official URL: http://www.ijbs.com/v10i2
Last Modified : 03 Feb 2016 11:18
Volume 10, Number 2, - 2014 , ISSN 1449-2288
Full Text Original